Menu
Back to Journals » Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (166)
- Volume 14, 2023 (6)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Journal Articles:
- 166 records -
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD
Lung Cancer: Targets and Therapy 2023, 14:47-55
Published Date: 19 May 2023
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Lee ATM, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:41-46
Published Date: 25 April 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Zhang SS, Lee A, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:27-30
Published Date: 19 April 2023
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A
Lung Cancer: Targets and Therapy 2023, 14:11-25
Published Date: 3 February 2023
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Brazel D, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:1-9
Published Date: 5 January 2023
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Brazel D, Arter Z, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:75-80
Published Date: 10 November 2022
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:67-73
Published Date: 25 October 2022
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW
Lung Cancer: Targets and Therapy 2022, 13:53-66
Published Date: 5 September 2022
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:47-52
Published Date: 19 May 2022
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Brazel D, Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2022, 13:33-45
Published Date: 13 May 2022
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:23-31
Published Date: 26 April 2022
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:13-21
Published Date: 29 March 2022
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma
Davis A, Ke H, Kao S, Pavlakis N
Lung Cancer: Targets and Therapy 2022, 13:1-12
Published Date: 2 March 2022
The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers
Vokes NI, Zhang J
Lung Cancer: Targets and Therapy 2021, 12:139-149
Published Date: 2 December 2021
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:133-138
Published Date: 2 December 2021
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Fitzpatrick O, Naidoo J
Lung Cancer: Targets and Therapy 2021, 12:123-131
Published Date: 2 November 2021
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang S, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:115-122
Published Date: 7 October 2021
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M
Lung Cancer: Targets and Therapy 2021, 12:103-114
Published Date: 7 October 2021
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H
Lung Cancer: Targets and Therapy 2021, 12:93-102
Published Date: 30 August 2021
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer
Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R
Lung Cancer: Targets and Therapy 2021, 12:81-92
Published Date: 16 August 2021
Targeting AXL in NSCLC
Zaman A, Bivona TG
Lung Cancer: Targets and Therapy 2021, 12:67-79
Published Date: 10 August 2021
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Zhang SS, Zhu VW
Lung Cancer: Targets and Therapy 2021, 12:61-65
Published Date: 12 July 2021
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Shukla N, Hanna N
Lung Cancer: Targets and Therapy 2021, 12:51-60
Published Date: 28 June 2021
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
Fujino T, Suda K, Mitsudomi T
Lung Cancer: Targets and Therapy 2021, 12:35-50
Published Date: 20 May 2021
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Giustini N, Bazhenova L
Lung Cancer: Targets and Therapy 2021, 12:21-34
Published Date: 25 March 2021
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW
Lung Cancer: Targets and Therapy 2021, 12:11-20
Published Date: 18 March 2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Yu D, Zhao W, Vallega KA, Sun SY
Lung Cancer: Targets and Therapy 2021, 12:1-10
Published Date: 5 February 2021
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B
Lung Cancer: Targets and Therapy 2020, 11:113-121
Published Date: 18 December 2020
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
Nagata I, Ogino T, Arimura T, Yoshiura T
Lung Cancer: Targets and Therapy 2020, 11:105-111
Published Date: 9 October 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Lung Cancer: Targets and Therapy 2020, 11:73-103
Published Date: 7 October 2020
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Lung Cancer: Targets and Therapy 2020, 11:59-71
Published Date: 7 September 2020
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T
Lung Cancer: Targets and Therapy 2020, 11:53-57
Published Date: 12 July 2020
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
Peri M, Fazio N
Lung Cancer: Targets and Therapy 2020, 11:41-52
Published Date: 8 July 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Lung Cancer: Targets and Therapy 2020, 11:33-39
Published Date: 17 April 2020
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
Kauffmann-Guerrero D, Huber RM
Lung Cancer: Targets and Therapy 2020, 11:27-31
Published Date: 2 March 2020
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K
Lung Cancer: Targets and Therapy 2020, 11:19-25
Published Date: 24 February 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI
Lung Cancer: Targets and Therapy 2020, 11:13-18
Published Date: 14 January 2020
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K
Lung Cancer: Targets and Therapy 2020, 11:1-11
Published Date: 8 January 2020
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
Inoue H, Okamoto I
Lung Cancer: Targets and Therapy 2019, 10:161-170
Published Date: 3 January 2020
Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Mix M, Tanny S, Nsouli T, Alden R, Chaudhari R, Kincaid R, Rosenbaum PF, Bogart JA, Aridgides P
Lung Cancer: Targets and Therapy 2019, 10:151-159
Published Date: 20 December 2019
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
Baldovini C, Rossi G, Ciarrocchi A
Lung Cancer: Targets and Therapy 2019, 10:131-149
Published Date: 5 December 2019
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Lung Cancer: Targets and Therapy 2019, 10:125-130
Published Date: 13 November 2019
Landscape on CT screening for lung cancer in Asia
Triphuridet N, Henschke C
Lung Cancer: Targets and Therapy 2019, 10:107-124
Published Date: 30 September 2019
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A
Lung Cancer: Targets and Therapy 2019, 10:95-105
Published Date: 12 September 2019
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Facchinetti F, Friboulet L
Lung Cancer: Targets and Therapy 2019, 10:87-94
Published Date: 9 September 2019
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR
Lung Cancer: Targets and Therapy 2019, 10:81-86
Published Date: 15 August 2019
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
Stratmann JA, Sebastian M
Lung Cancer: Targets and Therapy 2019, 10:67-80
Published Date: 1 July 2019
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A
Lung Cancer: Targets and Therapy 2019, 10:57-66
Published Date: 17 June 2019
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Weinberg F, Gadgeel S
Lung Cancer: Targets and Therapy 2019, 10:47-56
Published Date: 4 June 2019